



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/633,572	08/05/2003	Christian Klein	2923-553	5439
6449	7590 12/19/2005		EXAMINER	
ROTHWELL, FIGG, ERNST & MANBECK, P.C.			NGUYEN, BAO THUY L	
1425 K STRE	ET, N.W.			
SUITE 800			ART UNIT	PAPER NUMBÉR
WASHINGTON, DC 20005			1641	

DATE MAILED: 12/19/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/633,572	KLEIN ET AL.				
Office Action Summary	Examiner	Art Unit				
·	Bao-Thuy L. Nguyen	1641				
The MAILING DATE of this communication app						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 14 No.	ovember 2005.					
<u></u>	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.					
,—	) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-3,5-18 and 23-30</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
7) Claim(s) <u>1-3,5-78 and 23-30</u> is/are rejected.	6) Claim(s) 1-3,5-18 and 23-30 is/are rejected.					
8) Claim(s) are subject to restriction and/or	r election requirement.					
, , , , , , , , , , , , , , , , , , , ,	·					
Application Papers		•				
9) The specification is objected to by the Examine		Evenines				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔲 Interview Summary Paper No(s)/Mail Da					
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		Patent Application (PTO-152)				

Application/Control Number: 10/633,572 Page 2

Art Unit: 1641

## **DETAILED ACTION**

#### Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 11/14/2005 has been entered.

2. Claims 1-3, 5-18, 23-30 are pending.

# Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims 1-8, 15-18 and 23-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scholtissek et al (DE 41 21 493 A1 English Abstract) in view of Abuknesha et al (WO 93/11430) for reasons of record.

Scholtissek discloses a method and device in which air to be examined is passed through a filter and any narcotic contained in the air is selectively adhered or absorbed

on the filter. The adhered narcotic is eluted and dissolved in a solution and an antibody to the narcotic is mixed with the sample to detect the presence and amount of the narcotic. See English abstract.

Scholtissek differs from the instant invention in failing to teach a binding partner contained in the filter.

Abuknesha, however, discloses a device and method for collecting analyte in a gaseous medium. Abuknesha teaches that a binding partner for the analyte can be covalently linked or sorbed on to a carrier mean, i.e. a nitrocellulose membrane (pages 6 and 7) and the analyte from a gaseous phase is allowed to contact the binding partner and form a complex comprising the binding partner and the analyte. Abuknesha teaches the detection of complexed or uncomplexed binding partners as a measure of the analyte. Abuknesha also teaches a separation step as well as post reaction binding modification. See pages 12-21.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device and method taught by Scholtissek to include a binding agent in the carrier matrix such as taught by Abuknesha because Abuknesha teaches that it is well known in the art to include a reagent for capturing the analyte on a carrier means. A skilled artisan would have had a reasonable expectation of success in including a first capture reagent in a carrier matrix and using the carrier matrix to capture analyte in a gaseous sample because both Scholtissek and Abuknesha teaches using a filter material to capture analyte in gaseous samples, and Abuknesha

teaches that the incorporation of binding partner into a carrier matrix is conventional and well known as well as providing a convenient means to effectively capture minute amount of trace narcotic in the air.

5. Claims 9-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scholtissek et al in view of Abuknesha et al as applied to claims 1-8, 15-18 and 23-27 above, and further in view of Schlipfenbacher et al (US 5,160,486) for reasons of record.

The references of Scholtissek and Abuknesha have been discussed above. These references differ from the instant invention in failing to teach the liquid content of the carrier matrix.

Schlipfenbacher, however, teaches a test carrier for immunoassay comprising a fleece material. Schlipfenbacher discloses a variety of material with different water uptake and output properties. See column 10.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to choose any of the fleece material taught by Schlipfenbacher as the carrier means in the device and method taught by Scholtissek as modified by Abuknesha because Schlipfenbacher teaches that a special importance for the function of test carriers is the retention of water under certain defined experimental conditions, therefore, depending on the requirements of an assay, a skilled artisan would have had a reasonable expectation of success in choosing an appropriate fleece material according to the guidelines set forth by Schlipfenbacher. Furthermore, it has long been settled to be no more than routine experimentation for one of ordinary skill in

Application/Control Number: 10/633,572

Art Unit: 1641

the art to discover an optimum value of a result effective variable, and absent unexpected results, it would have been obvious for one of ordinary skill to discover the optimum workable ranges of the methods disclosed by the prior art by normal optimization procedures.

6. Claims 28-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Scholtissek in view of Abuknesha and Schlipfenbacher for reasons of record.

Even though these references fail to specifically state the gas permeability of the carrier matrix, they do teach carrier matrix permeable to gas and liquid, therefore, a skilled artisan would have a reasonable expectation of success in choosing the appropriate carrier matrix for use in the method and device of Scholtissek as modified by Abuknesha and Schlipfenbacher because it has long been settled to be no more than routine experimentation for one of ordinary skill in the art to discover an optimum value of a result effective variable. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum of workable ranges by routine experimentation." Application of Aller, 220 F.2d 454, 456, 105 USPQ 233, 235-236 (C.C.P.A. 1955). "No invention is involved in discovering optimum ranges of a process by routine experimentation." Id. at 458, 105 USPQ at 236-237. The "discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art." Application of Boesch, 617 F.2d 272, 276, 205 USPQ 215, 218-219 (C.C.P.A. 1980). Since Applicant has not disclosed that the specific limitations recited in instant claims are for any particular purpose or solve any stated problem and the

prior art teaches that the choice of an appropriate carrier matrix is dependent on the experimental conditions which often vary according to the sample being analyzed, various solutions and parameters appear to work equally as well, absent unexpected results, it would have been obvious for one of ordinary skill to discover the optimum workable ranges of the methods disclosed by the prior art by normal optimization procedures known in the art.

## Response to Arguments

7. Applicant's arguments filed 11/14/2005 have been fully considered but they are not persuasive.

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

Applicant argues that Scholtissek is mischaracterized in the office action because Scholtissek teaches a displacement assay and the filter of Scholtissek does not contain a first binding partner in an elutable form. Applicant also argues that a complex consisting of the analyte and first binding partner and uncomplexed first binding partner is not eluted from Scholtissek's device.

This argument is not persuasive. The Abstract of the Scholtissek reference clearly states that air to be examined is passed through a filter any narcotic contained in

**Art Unit: 1641** 

the air is selectively adhered or adsorbed on the filter. The adhered narcotic is dissolved in a solution (i.e. eluted) to produce a sample liquid and an antibody to the narcotic is mixed with the sample to detect the presence and mount of the narcotic. Scholtissek differs from the invention because the Abstract does not specifically define "selectively adhered", and does not make clear that the filter contains binding partner to the narcotic.

Abuknesha, however, discloses a device and method for collecting analyte in a gaseous medium. Abuknesha teaches that a binding partner for the analyte can be covalently linked or sorbed on to a carrier mean, i.e. a nitrocellulose membrane (pages 6 and 7) and the analyte from a gaseous phase is allowed to contact the binding partner and form a complex comprising the binding partner and the analyte. Abuknesha teaches the detection of complexed or uncomplexed binding partners as a measure of the analyte. Abuknesha also teaches a separation step as well as post reaction binding modification. See pages 12-21.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the device and method taught by Scholtissek to include a binding agent in the carrier matrix such as taught by Abuknesha because Abuknesha teaches that it is well known in the art to include a reagent for capturing the analyte on a carrier means. A skilled artisan would have had a reasonable expectation of success in including a first capture reagent in a carrier matrix and using the carrier matrix to capture analyte in a gaseous sample because both Scholtissek and Abuknesha

**Art Unit: 1641** 

teaches using a filter material to capture analyte in gaseous samples, and Abuknesha teaches that the incorporation of binding partner into a carrier matrix is conventional and well known as well as providing a convenient means to effectively capture minute amount of trace narcotic in the air. A skilled artisan would have had a reasonable expectation of success in eluting any complexes form between the narcotic of Scholtissek and binding agent of Abuknesha because Scholtissek teaches that the captured narcotic is eluted using a buffer (i.e. water), therefore, it would be expected that any reagents on the filter would be eluted along with the captured narcotic.

The argument that neither Scholtissek nor Abuknesha allows analyte elution from the carrier matrix is not persuasive. Scholtissek clearly teaches that the adhered narcotic is dissolved in a solution to produce a sample liquid.

Applicant argues that Schlipfenbacher does not cure the deficiency of Scholtissek and Abuknesha because Schlipfenbacher does not teach the elution of a complex between analyte and analyte binder nor does Schlipfenbacher teaches detection of analyte in a gaseous sample.

This argument is not persuasive. Schlipfenbacher is cited for their teaching of a fleece material for use as a test carrier for immunoassay. Scholtissek, as modified by Abuknesha, teaches the elution of analyte captured in a gaseous phase above.

Application/Control Number: 10/633,572 Page 9

Art Unit: 1641

### Conclusion

8. No claim is allowed.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao-Thuy L. Nguyen whose telephone number is (571) 272-0824. The examiner can normally be reached on Tuesday and Wednesday from 8:00 a.m. -4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bao-Thuy L. Nguyen Primary Examiner Art Unit 1641